Antiarrhythmic Drug Target Choices and Screening
نویسندگان
چکیده
منابع مشابه
The antiarrhythmic drug BRL-32872.
BRL-32872 is a new antiarrhythmic drug with balanced class-III and class-IV actions as categorized by the Vaughan-Williams classification. BRL-32872 blocks the rapid component of the cardiac delayed rectifier potassium channel IK(r) (IC(50) = 28 nM) and its molecular correlate HERG ("Human-ether-a-go-go related gene," IC(50) of 19.8 nM in cell lines) at low concentrations. It also inhibits the ...
متن کاملLidoflazine as an antiarrhythmic drug.
Since Schaper and his coworkers1-3 reported an excellent coronary vasodilating action of lidofiazine, a drug originally prepared in Janssen Pharmaceutica Institute, on conscious dogs with a previously implanted electromagnetic flow meter, the antianginal effect of the drug has been clinically investigated in our own and other laboratories. Its usual dose is 90 or 120mg per day. Recently, we adm...
متن کاملRadiofrequency Catheter Ablation and Antiarrhythmic Drug Therapy
Background—Information on comparative outcome between radiofrequency catheter ablation (RFA) and antiarrhythmic drugs (AADs) 1 year after randomization is important for clinical decision-making. Methods and Results—A total of 198 patients (age, 56 10 years) with paroxysmal atrial fibrillation were randomly assigned to RFA (99 patients) or to AADs (99 patients). We evaluated efficacy of RFA or A...
متن کاملAn emerging antiarrhythmic target: late sodium current.
The cardiac late sodium current (INa,L) has been in the focus of research in the recent decade. The first reports on the sustained component of voltage activated sodium current date back to the seventies, but early studies interpreted this tiny current as a product of a few channels that fail to inactivate, having neither physiologic nor pathologic implications. Recently, the cardiac INa,L has ...
متن کاملDual-Target Anticancer Drug Candidates: Rational Design and Simulation Studies
This study aims to design some dual-target anticancer candidates, capable to act as an alkylating agent as well as a thymidylate synthase (TS) inhibitor. The designed scaffold is a combination of nucleobase, amino acid and aziridine structures. The candidates are docked into TS and three DNA double strand structures and evaluated based on their binding interaction energies and ligand efficienci...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation Research
سال: 2003
ISSN: 0009-7330,1524-4571
DOI: 10.1161/01.res.0000091829.63501.a8